drugset / Trial / NCT01527916

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01527916

Phase 2 Completed 438 enrolled AbbVie
RandomizedParallel-groupTriple-blindTreatment

Summary

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Timeline

Start
2012-02
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-126 Small molecule 25 mg
Subject ABT-126 Small molecule 50 mg
Subject ABT-126 Small molecule 75 mg
Comparator Donepezil Small molecule 10 mg

Indications